Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8776 + Cytarabine in Relapsed AML
NCT01870596Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-8776 in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started May 2013; status: completed.
02
Drugs
MK-8776
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01870596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870596.